MARKET

UTHR

UTHR

United Therapeutics Corp.
NASDAQ
309.87
+3.83
+1.25%
Opening 15:39 06/20 EDT
OPEN
305.30
PREV CLOSE
306.04
HIGH
311.30
LOW
303.06
VOLUME
403.16K
TURNOVER
0
52 WEEK HIGH
311.30
52 WEEK LOW
208.62
MARKET CAP
13.75B
P/E (TTM)
14.66
1D
5D
1M
3M
1Y
5Y
United Therapeutics Reaches Analyst Target Price
NASDAQ · 1d ago
Weekly Report: what happened at UTHR last week (0610-0614)?
Weekly Report · 3d ago
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
United Therapeutics Corporation's (NASDAQ:UTHR) price-to-earnings ratio is 11.9x. The company is trading at a lower valuation than the market in the United States. Its earnings have grown by 159% over the past three years. The low P/E ratio may be due to investors' expectations of the company's future growth.
Simply Wall St · 06/13 15:06
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings)
United Therapeutics specializes in drug development for pulmonary arterial hypertension. The company has an average 12-month price target of $318.0. 5 analysts have recently analyzed the company. United Therapeutic has a high estimate of $400.00 and a low estimate of £240.00 for the next year.
Benzinga · 06/12 15:01
United Therapeutics Is Maintained at Overweight by Wells Fargo
Dow Jones · 06/12 12:37
United Therapeutics Price Target Raised to $350.00/Share From $325.00 by Wells Fargo
Dow Jones · 06/12 12:37
Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $350
Benzinga · 06/12 12:27
United Therapeutics: Poised for Growth in Pulmonary Hypertension Market, Underappreciated by the Market
TipRanks · 06/12 10:37
More
About UTHR
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

Webull offers United Therapeutics Corporation stock information, including NASDAQ: UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.